No Data
No Data
Marker Therapeutics Advances in Immuno-Oncology
Marker Therapeutics GAAP EPS of -$1.59, Revenue of $3.31M
Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter o
Press Release: Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response
Marker Therapeutics Ends Stock Sale Deal With LPC
Marker Therapeutics Receives Approval From United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of
No Data